AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01013532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ankle-brachial index (ABI)
Description: measurement of ABI every years during follow up
Study NCT01013532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ankle-brachial index (ABI)
Description: measurement of ABI every years during follow up
Study NCT01013532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intima-medial thickness (IMT)
Description: ultrasound measured IMT of both common carotid arteries
Study NCT00819169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
Study NCT01013532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intima-medial thickness (IMT)
Description: ultrasound measured IMT of both common carotid arteries
Study NCT01013532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: new asymptomatic brain hemorrhage
Description: asymptomatic macrobleedings or microbleedings on GRE images
Study NCT00819169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
Study NCT01013532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new asymptomatic brain hemorrhage
Description: asymptomatic macrobleedings or microbleedings on GRE images
Study NCT01013532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: new ischemic lesions on follow-up FLAIR images
Description: any new ischemic lesions
Study NCT02425176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A (BoNT-A) 100U
Description: The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Study NCT01013532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new ischemic lesions on follow-up FLAIR images
Description: any new ischemic lesions
Study NCT02425176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A (BoNT-A) 200U
Description: The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Study NCT04227340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy (PBM)
Description: The PBM will be delivered through application of the LED Cluster Probe externally to the right external buccal, left external buccal, mid face with mouth open and submandibular and left/right cervical. Patients who develop an oral lesion, intra-oral directed therapy will be administered with the dental light probe. For patients that can tolerate, an intraoral probe will deliver light directly onto the oral mucosa, this will then replace the mid face application with mouth open. Each laser application will be timed at 60 seconds.
Study NCT04227340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain and Oral Function Assessment
Description: After the 6-minute laser/ treatment session the child and parent will complete the mucositis evaluation scale on paper or ipad which includes self-report oral function specific to ability to swallow, eat and drink, as well as the patient's self-reported need for medication specific to mouth pain.
Study NCT04227340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent-Reported Satisfaction Survey
Description: A parent-reported satisfaction survey will be administered via paper questionnaire after the initial LLLT treatment. Parent satisfaction will be reported by parents on a 5-point Likert scale to questions adapted from a parent satisfaction survey used in a study regarding child life services in pediatric imaging.
Study NCT00974103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise advise
Description: Exercises
Study NCT00974103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chiropractic treatment and exercises
Description: Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
Study NCT03989713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRD-triggered arm
Description: 1. Salvage therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / >-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~2. Consolidation therapy:~   Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / >-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3~3. Observation therapy:~No treatment
Study NCT03989713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Arm
Description: 1. Salvage therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / >-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~2. Consolidation therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / >-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3;~3. Maintenance therapy:~Quizartinib: Cycle 1, Days 1-15: 40mg, p.o. and Day 16-28: 60mg, p.o.
Study NCT02462785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person Carbohydrate Counting Class
Description: An in-person carbohydrate counting class led by a registered dietician. The in class session covers topics including the role of CHO in nutrition and diabetes, sources of CHO, different CHO and non-CHO foods, resources for CHO counting, label reading, and meal planning. This is the standard procedure for CHO counting education at SickKids.
Study NCT02462785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Carbohydrate Counting Tutorial
Description: A web-based CHO counting tutorial that covers the same concepts reviewed during the standard in-person instructional session held at SickKids. A teen delivers the educational messages in short segments using techniques designed to maintain the viewer's attention (e.g., visuals of food portions and short segment highlights to emphasize important points). The online module includes brief interactive question/answer components for reinforcement. The secure online tutorial will be accessible for one week through a link provided by REDCap. Users will be able to repeat sessions, log on and off during sessions, and choose specific modules for repetition/review. The investigators will be able to capture the number of times patients log on and detail frequency and specifics of usage.
Study NCT04562506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS with H-coil
Description: Deep repetitive transcranial manetic stimulation or sham stimulation with H-coil
Study NCT04562506 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS stimulation with H-coil
Description: Sham rTMS stimulation
Study NCT01874574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Description: After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
Study NCT01874574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
Study NCT02157337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg (PO) once daily for 6 days
Study NCT02157337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 80 mg (PO) once daily for 6 days
Study NCT04634331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Multi-Modal Training
Description: Training administered via an augmented reality headset.
Study NCT04634331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Multi-Modal Training
Description: Training administered via a 1:1 physical therapy session
Study NCT01179620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin
Description: Certoparin
Study NCT03760666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brequinar/Brequinar + Ribavirin
Description: The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
Study NCT03292978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics intervention
Description: The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
Study NCT03292978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: non-probiotic control
Description: The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
Study NCT00705276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid (Dermacyd Femina Delicata)
Study NCT01844193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compex Rehab
Description: Participants in this arm will use a Compex® Rehab unit for neuromuscular electrical stimulation starting with postoperative at-home day 1 and continue using the unit twice a day, every day, until a 10-week follow-up is reached. The unit produces a 380 microsecond biphasic curve and utilizes a four phase process for the treatment (Warm-up, Work, Relaxation, and Recovery) for a total treatment time of 20 minutes and 5 seconds per session. All frequencies are delivered at the maximum subjective tolerable intensity. Participants will control this intensity and be asked to select a level that is tolerable although mildly uncomfortable; they will be instructed to increase this intensity as tolerated.
Study NCT00492804 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lichtenstein hernia repair
Description: Lichtenstein hernia repair with tension free mesh
Study NCT00492804 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neurectomy
Description: Neurectomy
Study NCT03952455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral surgical implantation of DBS system to Nucleus Accumbens
Description: We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
Study NCT03829631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618
Description: The brace is an FDA Class I, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks during the daytime
Study NCT01950260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
Study NCT01950260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to start at 4 weeks after RAI
Study NCT04656652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1062a
Description: DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
Study NCT04656652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
Study NCT01866241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Is a prostaglandin
Study NCT00543218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide 20 micrograms/day subcutaneous
Study NCT00543218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcitonin 100 IU/day subcutaneous
Study NCT05364918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jeksung combined with anti-radiation spray
Description: Treat radiation stomatitis with Jeksung combined with anti-radiation spray
Study NCT04643249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333
Description: Tablet
Study NCT04643249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Tablet
Study NCT04643249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Syrap
Study NCT04643249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Tablet
Study NCT04643249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: solution for injection
Study NCT04643249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Capsule
Study NCT02037880 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar puncture
Study NCT01197573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rTPA Treatment
Description: Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
Study NCT01197573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No TPA Treatment
Description: Standard of Care
Study NCT01248806 — intervention group
Intervention type: RADIATION
Intervention: Low dose CT scan
Description: A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
Study NCT01952015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
Study NCT03271827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apnoeic oxygenation
Description: 3 L/min of oxygen by nasal cannula during as apnoeic oxygenation during airway management.
Study NCT04311905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: Diode laser activated irrigation
Study NCT04311905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mock Laser activated irrigation
Study NCT01566344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVC suppression therapy
Description: Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
Study NCT02064218 — intervention group
Intervention type: DRUG
Intervention: Anti-hypertensive drugs
Study NCT03865069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mode of ventilation (Volume Guarantee)®
Description: This is a volume-targeted mode of ventilation aimed at delivering the set tidal volume of gas by automatically adjusting the peak inspiratory pressure (PIP) on a breath-by-breath basis. Theoretically this should minimise variation in tidal volume delivery as lung compliance and the infant's condition changes. This function is achieved by an automated servo-controlled mechanism. The upper PIP limit can be set by the clinician as a safety mechanism.
Study NCT03865069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mode of ventilation (Volume control Ventilation)
Description: Volume-Controlled ventilation (VCV) is a type of 'volume targeted' mode. It aims to target be supported the desired tidal volume by delivering a set volume (chosen by the clinician) irrespective of the underlying lung mechanics. The ventilator will generate whatever peak inspiratory pressure is necessary to deliver this volume. There is constant inspiratory flow pattern (a square flow waveform) and peak volume and inspiratory pressure delivery are achieved at the end of inspiration. During the 'control period' of 12 hours without VG, infants will using VCV A/C (assist control) as is our current clinical standard.
Study NCT00875771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine+Irinotecan+Bevacizumab
Description: * Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~* Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~* Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity.
Study NCT01732263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184
Description: All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Study NCT06451237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin capsules
Description: A one year follow up for patients on three maintenance regimens after acne clearance, including weekend isotretinoin and adapalene gel.
Study NCT01852864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 240mg degarelix s.c. injection
Description: 7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
Study NCT01494038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: 300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
Study NCT01494038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for isoniazid (INH)
Description: Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
Study NCT03133897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: experimental group will receive 2 day treatment
Study NCT04643249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Tablet or capsule
Study NCT04643249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Tablet
Study NCT03548636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-Arm Feasibility Study
Description: Groups of 8 to 12 participants, consisting of >50% breast cancer survivors, were invited to apply for up to $2000 to enable access to equipment, resources, facilities, instruction and/or transportation to implement a physical activity intervention. Applicants were assessed by a Grant Review Panel. Successful applicants were informed that they would receive an additional $500 incentive if they increased their group's mean physical activity at six month follow-up (assessed via accelerometry).
Study NCT02712112 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Imatinib Mesylate
Study NCT02712112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study NCT03508102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: the effects of remifentanil on the average value of BIS at the time period of before induction , induction , intubation , skin incision, peritoneum incision, uterine incision, and delivery
Study NCT04230980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 600mg tablet
Study NCT04230980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT02694614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone-assisted dietary coaching
Study NCT02309606 — intervention group
Intervention type: OTHER
Intervention: PET scan with 5-HT receptor ligands
Description: Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.
Study NCT00232843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Cordis SMART™ nitinol self-expanding stent.
Study NCT00232843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty
Description: balloon angioplasty
Study NCT03870503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: The patient will be received oxytocin 20 IU by intravenous infusion
Study NCT03870503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin plus misoprostol
Description: The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol
Study NCT03870503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: The patient received Carbetocin 100 mic gm
Study NCT04242875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Angle Kappa
Description: Angle kappa will be measured using the OPD III scan.